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Summary
 
Aberrant activation of cell cycle molecules has been postulated to play a role in apoptosis (“cat-
astrophic cell cycle”). Here we show that in noncycling developing thymocytes, the cyclin-
dependent kinase Cdk2 is activated in response to all specific and nonspecific apoptotic stimuli
tested, including peptide-specific thymocyte apoptosis. Cdk2 was found to function upstream
of the tumor suppressor p53, transactivation of the death promoter Bax, alterations of mito-
chondrial permeability, Bcl-2, caspase activation, and caspase-dependent proteolytic cleavage
of the retinoblastoma protein. Inhibition of Cdk2 completely protected thymocytes from apop-
tosis, mitochondrial changes, and caspase activation. These data provide the first evidence that
Cdk2 activity is crucial for the induction of thymocyte apoptosis.
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A
 
poptosis or programmed cell death (PCD) is required
for all multicellular organisms to maintain the homeo-
stasis of their organ systems. Failure to invoke effective pro-
grammed cell death can result in developmental abnormal-
ities, cancer, or autoimmune diseases, whereas increased
apoptosis produces degenerative diseases of the brain or
immunodeficiencies (1). Apoptosis can be triggered by
numerous different stimuli, all of which converge at the
common checkpoint of mitochondrially regulated death
induction (1–4) and caspase activation (5–9).
Apoptosis and mitosis have many features in common,
including cytoskeletal changes, nuclear envelope break-
down, and chromatin condensation, and it has been specu-
lated that apoptosis may result from a form of aberrant cell
cycling called “catastrophic mitosis” (10–12). This idea is
supported by the fact that various gene products that have
marked effects on cell cycle control, such as p53, retino-
blastoma protein (Rb),
 
1
 
 Cdc25, Max, c-Myc, or E2F-1,
also regulate susceptibility to apoptosis (13–20). Thus, it has
been shown that overexpression of the tumor suppressor
p53 can induce either growth arrest or apoptosis, depend-
ing on the cell type (21). Conversely, loss of p53 function
in mice produces resistance to apoptotic stimuli such as
 
g
 
-irradiation (22, 23). Furthermore, deficiency of another
cell cycle regulator, E2F-1, in mice resulted in an enlarged
thymus in these mutant mice, implying a possible role of
E2F-1 as a proapoptotic molecule (19, 20). Inversely, the
loss of the tumor suppressor and cell cycle regulator Rb in
mice leads to increased cell death, further confirming the
close interaction between apoptotic pathways and cell cycle
pathways (24).
Members of the cyclin-dependent kinase (Cdk) family of
serine/threonine kinases are known to be key regulators of
eukaryotic cell cycle progression (25). Different Cdk cata-
lytic subunits and their activating cyclin subunits operate as
control checkpoints during cell cycle progression. Cdk2 is
crucial for the progression from the G1 to the S phase of
the cell cycle. Inhibition of Cdk2 activity in vitro has been
shown to protect cultured sympathetic neurons and heart
muscle cells from apoptosis (26, 27). However, Cdk2 inhi-
bition can also lead to cell death in tumor cell lines (28).
Whether Cdk2 and the aberrant activation of the cell cycle
machinery have an apoptotic function necessary for normal
development has yet to be addressed.
CD4
 
1
 
CD8
 
1
 
 thymocytes are noncycling cells which are
sensitive to many apoptotic stimuli in vitro and in vivo, in-
cluding glucocorticoids, ionizing irradiation, heat shock,
and CD95 (9). Physiologically, CD4
 
1
 
CD8
 
1
 
 thymocytes
undergo negative selection and clonal deletion required for
the induction and maintenance of immunological tolerance
(29). We report in developing thymocytes that Cdk2 is ac-
tivated in response to all specific and nonspecific apoptotic
stimuli tested, including 
 
g
 
-irradiation and peptide-specific
 
1
 
Abbreviations used in this paper:
 
 aa, amino acid(s); Cdk, cyclin-dependent
kinase; 
 
DC
 
m
 
, mitochondrial transmembrane potential; FTOC, fetal thy-
mic organ culture; GST, glutathione 
 
S
 
-transferase; LCMV, lympholytic
choriomeningitis virus; PI, propidium iodide; PK, protein kinase; Rb,
retinoblastoma protein; Tg, transgenic. 
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negative thymocyte selection. Inhibition of Cdk2 com-
pletely prevented all aspects of thymocyte apoptosis and
blocks peptide-specific thymocyte death.
 
Materials and Methods
 
Mice.
 
p53 gene–deficient, Bcl-2 transgenic (Tg), DO.11.10
OVA TCR-
 
a
 
/
 
b
 
 Tg, and P14 TCR-
 
a
 
/
 
b
 
 Tg mice have been de-
scribed previously (30–33). BALB/c mice were purchased from
Taconic Farms. All mice were kept at the Animal Facility of the
Ontario Cancer Institute in accordance with institutional guide-
lines.
 
Apoptosis Induction and Inhibitors.
 
Freshly isolated thymocytes
from BALB/c mice were cultured in RPMI 1640 medium (10%
FCS, 10
 
2
 
5 
 
M 
 
b
 
-mercaptoethanol) in the absence or presence of
dexamethasone (Sigma), heat shock, 
 
g
 
-irradiation, anti-CD95 Ab
(clone Jo91; PharMingen), anti-CD3
 
e
 
 (clone 145-2C11; Phar-
Mingen), PMA (12.5 ng/ml), or etoposide (2.5 
 
m
 
g/ml) for differ-
ent time periods and at different concentrations as indicated in the
figure legends (34). Optimal concentrations and activation re-
gimes for the induction of apoptosis were determined in pilot
studies. The specific Cdk2 blockers olomoucine (Calbiochem)
and roscovitine (gift of Dr. Meijer, CNRS, Roscoff, France) were
dissolved in DMSO (Sigma). Titration experiments determined
that 100 
 
m
 
M olomoucine and 50 
 
m
 
M roscovitine were the most
effective concentrations for inhibiting Cdk2 activity and apopto-
sis in thymocyte cultures. DMSO had no effect on Cdk2 activity
or the induction or prevention of apoptosis in response to all
stimuli tested. The cell cycle blockers TGF-
 
b
 
 (1 nM; R&D Sys-
tems) and rapamycin (2 ng/ml; Calbiochem) were used at con-
centrations that optimally blocked cell cycle progression in T cell
lymphoma cells.
 
Detection of Apoptosis.
 
Total cell numbers of viable and apop-
totic cells were determined by trypan blue exclusion. Relative
percentages of viable and apoptotic CD4
 
1
 
CD8
 
1
 
 thymocytes
were determined by triple staining with anti-CD4–PE, anti-
CD8–FITC, and the vital chromogenic dye, 7AAD (34). The re-
sults were expressed as the percentage of viable thymocytes re-
maining after 22 h, calculated as follows: (number of viable
CD4
 
1
 
CD8
 
1
 
 thymocytes after stimulation)/(number of viable
CD4
 
1
 
CD8
 
1
 
 thymocytes cultured under the same conditions in
the absence of stimulation) 
 
3
 
 100. For the detection of cycling
and apoptotic cells, thymocytes were stained with propidium io-
dide (PI). After different periods of stimulation, thymocytes were
harvested, washed once in PBS (0.5% glucose), and fixed in cold
70% ethanol overnight. Fixed cells were pelleted to remove etha-
nol and stained with PI (final concentration 50 
 
m
 
mol/ml) for
30 min at room temperature. Apoptosis-mediated membrane
changes were determined via staining with Annexin V (R&D
Systems). PI and Annexin V staining of thymocytes was deter-
mined by cytofluorometry using a FACSCalibur™ (Becton Dick-
inson).
 
Kinase Assays.
 
After different periods of stimulation, thy-
mocytes were harvested and lysed, and proteins were immuno-
precipitated using Abs against Cdk2 (amino acids [aa] 283–298),
Cdk4 (aa 282–303), and Cdc2 (aa 278–297) (all from Santa Cruz
Biotechnology). Cdk2 and Cdc2 kinase activities in immunopre-
cipitates were assayed using [
 
g
 
-
 
32
 
P]ATP (3,000 cpm/pmol) and
histone H1 (2 
 
m
 
g/ml; Boehringer Mannheim) or p53 (2 
 
m
 
g/ml;
PharMingen) as substrates. Cdk4 activity was determined using
glutathione 
 
S
 
-transferase (GST)-Rb as a substrate (2 
 
m
 
g/ml;
PharMingen). H1, p53, or GST-Rb phosphorylation was assayed
by autoradiography after SDS-PAGE separation. The levels of
immunoprecipitated Cdk2, Cdc2, and Cdk4 were determined by
Coomassie blue staining and Western blotting.
 
Immunoprecipitations and Western Blotting.
 
Thymocytes were
lysed in 1% NP-40 lysis buffer. Proteins were separated by SDS-
PAGE, transferred onto nitrocellulose membranes, and incubated
with Abs reactive to Cdc2, Cdk2, Cdk4, Cdk7, Pctaire-2, Cdc25A,
cyclins A, E, D1, D2, B, and D3, E2F-1, p27
 
Kip1
 
, caspase 2, and p53
(clone 240) (all from Santa Cruz Biotechnology), p21 (Calbio-
chem), Bcl-XL (Transduction Laboratories), Bcl-2 (PharMingen),
caspase 3 (gift of Dr. R. Sekaly, McGill University, Montreal,
Quebec, Canada), and Rb (clone G3-245 reactive to an aa 300–380
epitope of Rb, PharMingen; and clone C-15 reactive against aa
914–928, Santa Cruz Biotechnology). The anti-caspase 8–specific
Abs were developed in our Institute and were a kind gift of Dr. R.
Hakem (Amgen Institute). Immunoprecipitations were performed
using protein A–Sepharose. Optimal Ab concentrations and condi-
tions for immunoprecipitations were determined in pilot studies.
 
DC
 
m
 
 Disruption.
 
The mitochondrial transmembrane poten-
tial (
 
DC
 
m
 
)
 
 
 
results from the asymmetric distribution of protons
across the inner mitochondrial membrane, giving rise to a chem-
ical (pH) and electric gradient (35, 36). The inner side of the
inner mitochondrial membrane is negatively charged. As a con-
sequence, the cationic lipophilic fluorochrome 3,3
 
9
 
-dihexylox-
acarbocyanine iodide (DiOC
 
6
 
(3)) is distributed on the mitochon-
drial matrix as a function of the Nernst equation, correlating with
 
DC
 
m
 
. DiOC
 
6
 
(3) can be used to measure variations in the 
 
DC
 
m
 
on a per-cell basis. Cells induced to undergo apoptosis manifest
an early reduction in the incorporation of 
 
DC
 
m
 
-sensitive dyes,
indicating a disruption of 
 
DC
 
m
 
. For DiOC
 
6
 
(3) staining, 10
 
6
 
 thy-
mocytes were incubated with DiOC
 
6
 
(3) (final concentration 20
nM in PBS) for 20 min at 37
 
8
 
C. DiOC
 
6
 
(3) staining was analyzed
immediately using a FACSCalibur™.
 
In Vitro Negative Thymocyte Selection.
 
Thymocytes were puri-
fied from P14 Tg mice, which express an 
 
a
 
/
 
b
 
 TCR (TCR
V
 
a
 
2V
 
b
 
8) specific for a peptide (p33) of the lympholytic chori-
omeningitis virus (LCMV). P14 Tg thymocytes (10
 
6
 
/well) were
cultured on a monolayer of confluent and adherent MC57/L
fibroblasts (H-2
 
b/b
 
) in RPMI medium (5% FCS, 10
 
2
 
5 
 
M 
 
b
 
-mer-
captoethanol). MC57/L APCs were pulsed with different con-
centrations of the deleting LCMV-p33 peptide for 2 h before
coculture with thymocytes. Thymocytes were harvested after 22 h
incubation and stained with anti-CD4–PE, anti-CD8–FITC, and
the dye, 7AAD. Percent survival was calculated as follows: (total
number of viable CD4
 
1
 
CD8
 
1
 
 thymocytes cultured at different
LCMV-peptide concentrations)/(total number of viable CD4
 
1
 
CD8
 
1
 
 thymocytes cultured with MC57/L cells at 37
 
8
 
C in the
absence of peptide) 
 
3 
 
100. Total numbers of viable and dead
cells were determined by trypan blue exclusion. For detection of
Cdk2 activity in peptide-activated thymocytes, P14 Tg thy-
mocytes (10
 
7
 
/well) were cultured on a monolayer of confluent
(noncycling) and adherent MC57/L fibroblasts pulsed with 10
 
2
 
5 
 
M
of the deleting p33 peptide (37, 38). After 5 h incubation, thy-
mocytes were separated from adherent fibroblasts and subjected
to Cdk2 kinase assays as above.
 
Fetal Thymic Organ Culture.
 
DO.11.10 males were mated with
estrous BALB/c females. On day 16 of gestation, pregnant
females were killed and embryonic thymi were harvested and
placed in culture. Thymi were microdissected and placed on the
surface of 0.8-mm filters (Nucleopore) resting on Gelfoam gela-
tin sponges (Upjohn) in RPMI 1640 medium supplemented with
10% FCS. Each sponge was placed into a 3.5-cm plastic dish in 2 ml
of medium. Cultures were incubated at 37
 
8
 
C. Chicken (c)OVA 
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protein was added at 1 mg/ml on day 1 of culture, and thymi
were analyzed 20 and 40 h later. Cell numbers were determined
by counting in the presence of trypan blue.
 
Results
 
Cdk2 Kinase Activity in Thymocyte Apoptosis.
 
To determine
whether the cell cycle machinery has a role in apoptosis of
noncycling G1 CD4
 
1
 
CD8
 
1
 
 thymocytes, we analyzed the
activity of several Cdks in these cells. Freshly isolated thy-
mocytes were treated with different death stimuli such as
dexamethasone, heat shock, 
 
g
 
-irradiation, and CD95 for
different time points, and Cdk activities of stimulated as
well as control thymocytes were assessed in in vitro kinase
assays. Surprisingly, increased activity of the cyclin-depen-
dent kinase Cdk2 was detected within 30 min of dexa-
methasone activation and peaked at 5 h (Fig. 1 A). Cdk2 ac-
tivity was rapidly increased in response to all apoptotic
stimuli tested, including dexamethasone, anti-Fas (CD95)
cross-linking, heat shock, or 
 
g
 
-irradiation (Fig. 1 B). No
changes in the kinase activities of Cdk4 or Cdc2 were ob-
served after induction of apoptosis (Fig. 1, A and C). Cdc2
activation was also not observed using an anti-Cdc2 phos-
phorylation epitope-specific Ab indicative of Cdc2 activa-
tion. Cdc2 and Cdk4 activities were readily detectable in
cycling T lymphoma cells (not shown). The expression
levels of molecules involved in the cell cycle, such as Cdk2,
Cdk4, Cdc2, Cdk7, Pctaire-2, Cdc25A, cyclins A, B, D1,
D2, D3, and E, p21, p27
 
Kip1
 
, and E2F-1, did not change 5 h
after stimuli (not shown). Cdk2 was found to bind to cy-
clin A and E thymocytes after treatment with dexametha-
sone and 
 
g
 
-irradiation. Immunoprecipitations of both cy-
clin A and cyclin E showed that after 
 
g
 
-irradiation or
dexamethasone, histone H1 was phosphorylated, suggest-
Figure 1. Induction of Cdk2 kinase ac-
tivity in response to apoptotic stimuli. (A)
Kinetics of Cdk2 and Cdc2 activity after
dexamethasone treatment. Freshly isolated
thymocytes were cultured in the absence or
presence of dexamethasone (1 mM), and
Cdk2 and Cdc2 activities were assessed. Af-
ter the indicated periods of stimulation, cells
were harvested and lysed, and proteins were
immunoprecipitated using Abs against Cdk2
and Cdc2. Cdk2 and Cdc2 kinase activities
in immunoprecipitates were assayed using
[g-32P]ATP and histone H1 as the substrate.
One result representative of four indepen-
dent experiments is shown. (B) Induction of
Cdk2 activity in thymocytes in response to
dexamethasone (1 mM), heat shock (428C
for 1 h), anti-CD95 (1 mg/ml), and g-irra-
diation (500 rads). Thymocytes were har-
vested 5 h after stimulation. Top panel, his-
tone H1 phosphorylation; middle panel,
level of Cdk2 protein; bottom panel, kinase
activity measured in arbitrary units normal-
ized to background protein and kinase lev-
els. One result representative of five inde-
pendent experiments is shown. (C) Activity
of Cdc2 and Cdk4 after induction of apop-
tosis. Thymocytes were cultured with dex-
amethasone (Dex) to induce apoptosis. Af-
ter 5 h, cells were lysed and Cdk4 and Cdc2
were immunoprecipitated. Cdc2 and Cdk4
kinase activities were determined using his-
tone H1 and GST-Rb as substrates, respec-
tively. (D) Blockage of Cdk2 activity in
thymocytes by specific inhibitor roscovitine
(50 mM) after dexamethasone (Dex) treat-
ment. Similar results were obtained using
the Cdk2 blocker olomoucine. Note the
background kinase activity of Cdk2 in A, B,
and D which is due to the spontaneous apop-
tosis of thymocytes in culture (z20% of
thymocytes die within 24 h by default).
Blockage of Cdk2 inhibits this form of de-
fault death and even after 1 wk in culture,
.90% of thymocytes were viable in the
presence of roscovitine or olomoucine (not
shown). (E) Activity of Cdk2–cyclin A or Cdk2–cyclin E complexes on histone H1 after dexamethasone (1 mM) treatment. Cyclin A or cyclin E was
immunoprecipitated using specific Abs, and kinase assays were performed as in A. 
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ing that both cyclin A and cyclin E have a role in Cdk2 ac-
tivation (Fig. 1 E). These results show that the induction of
thymocyte apoptosis by dexamethasone, 
 
g
 
-irradiation, heat
shock, or CD95 cross-linking leads to the activation of the
cell cycle regulator Cdk2.
 
Inhibition of Cdk2 Blocks Thymocyte Apoptosis.
 
To test
whether Cdk2 activity was required for the induction of
thymocyte apoptosis, the effects of two specific inhibitors
of Cdk2, olomoucine and roscovitine (39, 40), were exam-
ined. These inhibitors are purine analogues that selectively
inhibit the activity of Cdk2 and Cdc2 by specific binding
to the ATP-binding pocket. Both molecules completely
inhibited dexamethasone-induced Cdk2 activation in thy-
mocytes (Fig. 1 D), and blocked thymocyte apoptosis after
stimulation with dexamethasone, heat shock, 
 
g
 
-irradiation,
PMA, or the DNA damaging agent, etoposide (Fig. 2 A).
PI staining confirmed that thymocytes were in the G1
phase of the cell cycle and that induction of apoptosis did
not correlate with cell cycle progression (Fig. 2 D). A
“point of no return” was reached between 15 and 30 min
after treatment with the apoptotic stimulus such that a
Cdk2 blocker added after this time was unable to prevent
apoptosis (Fig. 2 B). Addition of other cell cycle blockers
such as TGF-
 
b
 
1 or rapamycin, used at the optimal concen-
trations, had no effect on the kinetics or extent of thy-
mocyte death (Fig. 2 C). Interestingly, although CD95
cross-linking led to strong Cdk2 activation (Fig. 1 B),
Cdk2 blockers did not inhibit CD95-mediated thymocyte
death (Fig. 2 A). In fact, CD95-mediated apoptosis was
consistently enhanced in the presence of the Cdk2 block-
ers. These results imply that CD95 uses a pathway other
than the one used by the other inducers, i.e., a receptor/
caspase 8 pathway instead of a nucleus/mitochondrial/
caspase 9 pathway (41). It should be noted that in our
screen, CD95 activation is the only thymocyte death stim-
ulus so far that cannot be blocked by Cdk2 inhibition.
 
Cdk2 Kinase Activity Is Required for Peptide-specific Thymo-
cyte Apoptosis.
 
The process of clonal deletion and selection-
triggered thymocyte death is a fundamental mechanism
required for the maintenance of lymphocyte homeostasis
and immunotolerance. CD4
 
1
 
CD8
 
1
 
 thymocytes expressing
TCRs which recognize self-antigens with high affinity/
Figure 2. Inhibition of apoptosis by Cdk2 blockers. (A) CD41CD81
thymocyte apoptosis in response to various death stimuli. Thymocytes
(2 3 106/well) were cultured in the absence of stimulation (Control), or
with dexamethasone (1 mM), heat shock (428C for 1 h), g-irradiation
(500 rads), anti-CD95 (1 mg/ml), plate-bound anti-CD3e (10 mg/ml),
etoposide (2.5 mg/ml), or PMA (12.5 ng/ml) in the absence (black bars,
Control) or presence of olomoucine (100 mM; white bars, Cdk2-inhibi-
tor). After 22 h, thymocytes were harvested and apoptosis was deter-
mined. Similar results were obtained using roscovitine (not shown). 1 re-
sult representative of 15 independent experiments is shown. (B) Time
course for the action of the Cdk2 inhibitors. Thymocytes were cultured
in the presence of dexamethasone (1 mM), and olomoucine (100 mM)
was added at the different indicated times. The “point of no return” is be-
tween 15 and 30 min. (C) Thymocytes were cultured in the absence of
stimulation (Control) or with dexamethasone (1 mM) in the absence
(Control) or presence of rapamycin (2 ng/ml) or TGF-b1 (1 nM). Thy-
mocyte apoptosis was determined 24 h after addition of dexamethasone. (D) Cell cycle status and apoptosis of thymocytes. Thymocytes were activated
with the indicated stimuli (as described for A) in the absence (Control) or presence of olomoucine (Cdk2-inhibitor). No (activation) indicates a culture
not treated with death-inducing stimuli. After 5 h, cells were harvested and stained with PI. The subdiploid (,G1) peak represents the number of apop-
totic cells among total cells. Cell cycle phases (G1, S, G2/M) are indicated. Numbers indicate the percentages of viable cells in the G1, S, and G2/M pop-
ulations. 1 result representative of 10 independent experiments is shown.961 Hakem et al.
avidity are clonally deleted via apoptosis, leading to the re-
moval of T cells that express TCRs with potentially harm-
ful self-reactivity (thymic tolerance [29]). To test whether
Cdk2 is a physiological regulator of thymocyte apoptosis,
we induced apoptosis of CD41CD81 immature thymo-
cytes by anti-CD3 cross-linking (42). Fig. 2 A shows that
Cdk2 inhibitors were able to block anti-CD3–mediated
apoptosis of immature thymocytes.
To further investigate the role of Cdk2 in clonal dele-
tion, we used an in vitro negative selection system using
thymocytes from P14 Tg mice. P14 Tg mice express a re-
arranged TCR a/b chain reactive to the p33 peptide of
LCMV. P14 Tg CD41CD81 thymocytes undergo apopto-
sis after culture with APCs pulsed with different concentra-
tions of the deleting p33 peptide. Thymocytes from P14
Tg mice underwent apoptosis in a p33 peptide dose-
dependent fashion which was inhibited by the addition of
Cdk2 blockers (Fig. 3 A). Importantly, induction of pep-
tide-specific apoptosis of P14 Tg thymocytes triggered
Cdk2 kinase activity (Fig. 3 B). Inhibition of Cdk2 did not
interfere with TCR-mediated proximal signaling events or
with TCR internalization, which is a functional measure of
antigen receptor–mediated activation (not shown). More-
over, inhibition of Cdk2 by olomoucine blocked OVA-
mediated negative selection of CD41CD81 OVA-speci-
fic TCR Tg thymocytes in fetal thymic organ cultures
(FTOCs; Fig. 3 C). Cdk2 blockers did not interfere with
positive thymocyte selection in reaggregation culture assays
(not shown), indicating that Cdk2 has a specific role in
peptide-specific thymocyte apoptosis.
Cdk2 Acts Upstream of Mitochondrial Permeability Transi-
tion, Bcl-2, and Caspases. Where does Cdk2 function in
the hierarchy of apoptosis? Disruption of DCm due to the
opening of mitochondrial pores has been invariably associ-
Figure 3. Cdk2 kinase is activated in
peptide-specific thymocyte apoptosis. (A)
Inhibition of Cdk2 blocks induction of pep-
tide-specific apoptosis of P14 Tg thy-
mocytes, which express an a/b TCR
(TCRVa2Vb8) specific for p33 peptide of
LCMV. Purified P14 Tg thymocytes were
cultured on p33 glycoprotein peptide–
pulsed MC57/L fibroblasts in the absence
(Peptide) or presence of roscovitine (50
mM; Peptide1Cdk2-inhibitor). Thymo-
cytes were harvested after 22 h incubation
and stained with anti-CD4–PE and anti-
CD8–FITC. Percent survival was calculated
as follows: (total number of viable CD41
CD81 thymocytes cultured at a given con-
centration of p33 peptide)/(total number of
viable CD41CD81 thymocytes cultured
with MC57/L cells at 378C in the absence
of peptide) 3 100. Molarity of peptide con-
centrations is shown on the x-axis. Cells
were harvested after 22 h of culture, and cell
death was determined. Numbers are the
percentages of viable CD41CD81 thy-
mocytes cultured at various p33 peptide
concentrations compared with control thy-
mocytes cultured in the absence of p33 pep-
tide (Control). Apoptosis of P14 thy-
mocytes in the presence of roscovitine alone
is also shown (Cdk2-inhibitor). Similar re-
sults were obtained using olomoucine (not
shown). One result representative of five in-
dependent experiments is shown. (B) In-
duction of Cdk2 kinase activity by peptide-
specific negative selection. P14 Tg thy-
mocytes (106/well) were cultured on a
monolayer of adherent MC57/L fibroblasts
(H-2b/b) in the presence or absence of the
deleting p33 peptide. After 5 h of culture,
thymocytes were harvested, Cdk2 was im-
munoprecipitated, and Cdk2 activity was
assessed using histone H1 as substrate. (C)
Cdk2 inhibitors prevent cOVA protein
(Ova-protein)–induced apoptosis of OVA-
specific TCR Tg thymocytes in FTOCs.
Thymi were removed at embyronic day 16
and cultured with olomoucine (100 mM)
and cOVA protein (1 mg/ml). Percentages
of viable thymocytes were determined.962 Cdk2 in Thymocyte Apoptosis
ated with apoptosis and is an early common denominator
of cell death (43). Alterations in mitochondria lead to the
release through the outer mitochondrial membrane of mol-
ecules such as cytochrome c and the apoptosis-inducing
factor (AIF), and the activation of the caspase cascade (7,
35, 36, 44–48).
To assess whether Cdk2 acts upstream or downstream of
mitochondrial events, we examined changes in DCm using
cytometry and the fluorochromic dye, DiOC6(3). Thy-
mocytes were stimulated either with dexamethasone or
anti-CD95, and the mitochondria changes of DCm were
assessed at different time points. The first changes in thy-
mocyte DCm were observed 2 h after dexamethasone treat-
ment, and DCm was significantly disrupted after 5 h (Fig. 4
A). Addition of Cdk2 inhibitors blocked dexamethasone-
induced losses of DCm (Fig. 4 A). CD95-mediated DCm
disruption and apoptosis still occurred in the presence of
Cdk2 inhibitors (Figs. 2 A and 4 A), implying that Cdk2
inhibition per se does not interfere with opening of mito-
chondrial pores. Since DCm is regulated by Bcl-2 family
members (43, 49), we also tested Cdk2 activation in Bcl-2
Tg thymocytes (31, 50). Although overexpression of Bcl-2
protected thymocytes from dexamethasone- and irradia-
tion-induced cell death and disruption of DCm (31, 50),
Cdk2 was still activated in Bcl-2 Tg thymocytes in re-
sponse to these apoptotic stimuli (not shown).
Caspase activation is a crucial event in apoptosis, and
caspases can function upstream or downstream of mito-
chondrial DCm disruption (8, 9). To determine where
Cdk2 acts during apoptosis with regard to the caspase acti-
vation cascade, processing of different caspases was assessed
in thymocytes after treatment with different apoptotic
stimuli in the presence or absence of Cdk2 inhibitors.
Within 2 h after dexamethasone and g-irradiation, caspase
3 (Cpp32) and caspase 8 activation was observed in thymo-
cytes whereas caspase 2 (nedd2) processing was first observed
3 h after death induction. Caspase activation peaked at 5 h
after induction of cell death (Fig. 4 B, and data not shown).
Figure 4. Cdk2 acts upstream of mitochondrial permeability transition, caspase activa-
tion, and Rb cleavage. (A) Mitochondrial permeability transition (DCm disruption). Thy-
mocytes were cultured for 5 h in medium alone, or in medium containing dexamethasone
(1 mM) or anti-CD95 (1 mg/ml) in the presence or absence of roscovitine (50 mM). Cells
induced to undergo apoptosis manifest an early reduction in the incorporation of DCm-
sensitive dyes, indicating a disruption of DCm. For DiOC6(3) staining, 106 thymocytes
were incubated with DiOC6(3) (final concentration 20 nM in PBS) for 20 min at 378C.
DiOC6(3) staining was analyzed immediately using a FACSCalibur™ flow cytometer.
One result representative of three independent experiments is shown. (B) Thymocytes
were stimulated with the indicated death stimuli for 5 h, and proteolytic activation of
caspase 3 (Cpp32) was assessed by Western blotting. The anti–caspase 3 Ab recognizes both the intact caspase 3 molecule (procaspase 3) and its cleaved
17-kD active form (p17). Addition of roscovitine inhibits caspase 3 cleavage in response to dexamethasone (right) and in response to all other death stim-
uli tested, except for anti-CD95. (C) Thymocytes were stimulated with the indicated stimuli, and the proteolytic activation of caspase 2 (Nedd2) was as-
sessed by Western blotting. The addition of roscovitine (Rosco) after irradiation blocked caspase 2 cleavage into a p14 fragment. (D) The retinoblastoma
protein Rb is proteolytically processed in response to all cell death stimuli. Inhibition of Cdk2 blocked Rb cleavage. Thymocytes were stimulated with
dexamethasone and g-irradiation in the presence or absence of roscovitine (Rosco, 50 mM). After 5 h, cells were harvested and lysed, and the status of
Rb was assessed by Western blotting. Rb-reactive Ab recognizes aa 300–380 of Rb. As previously described in cell lines (reference 53), Rb was cleaved
of the COOH-terminal end in apoptotic thymocytes in response to all apoptotic stimuli.963 Hakem et al.
However, activation of caspase 3 (Fig. 4 B), caspase 2 (Fig.
4 C), or caspase 8 (not shown) did not occur after blocking
of Cdk2 kinase activity. These results show that Cdk2 acts
upstream of Bcl-2, DCm, and caspases.
Proteolytic Processing of the Retinoblastoma Protein in Thy-
mocyte Apoptosis. During apoptosis, various cell cycle reg-
ulatory molecules such as p21 and Rb are proteolytically
cleaved by caspases. In particular, proteolytic processing of
the G1 to S cell cycle gatekeeper Rb (DRb) has been pre-
viously reported in TNF- and CD95-treated tumor cell
lines (51, 52). Rb and Cdk2 were found to coimmunopre-
cipitate in developing thymocytes (not shown). Induction
of thymocyte apoptosis in response to dexamethasone, irra-
diation, heat shock, or anti-CD95 correlated with the ap-
pearance of a second smaller Rb protein (DRb; Fig. 4 D).
Although it has been shown that Rb is cleaved by caspase 3
(53) and in thymocytes DRb was found to be a proteolytic
cleavage product of Rb mediated by caspases, DRb was still
observed in caspase 3 gene–deficient mice (not shown).
The earliest detectable Rb cleavage (DRb) occurred 5 h
after dexamethasone treatment (Fig. 4 D). Cdk2 inhibitors
or transgenic overexpression of Bcl-2 in thymocytes pre-
vented cleavage of Rb in response to dexamethasone (Fig.
4 D, and data not shown). These results demonstrate that
Cdk2 acts upstream of mitochondrial pore opening, Bcl-2,
caspase activation, and proteolytic cleavage of the cell cycle
regulator Rb. The functional consequences of Rb cleavage
are not known. Since DRb can only be observed down-
stream of the caspase effector phase and still binds to Cdk2
(not shown), the generation of DRb might function as a
regulatory feedback loop that could influence Cdk2 and/or
E2F-1 activity.
Cdk2 Is Upstream of p53 and Bax Expression in Irradiated
Thymocytes. How is Cdk2 activity mechanistically linked
to apoptotic mitochondrial events? Various members of the
Bcl-2 family of mitochondrial gatekeepers are phosphory-
lated on serine/threonine residues (9, 49). Although Bcl-2
and Bcl-XL contain consensus sites for Cdk2 activity, we
could not detect Cdk2-mediated phosphorylation of either
Bcl-2 or Bcl-XL in in vitro kinase assays (not shown). The
tumor suppressor p53 is a substrate for Cdk2 in the DNA
repair response (54), and thymocytes mutated in p53 are re-
sistant to g-irradiation–induced apoptosis but still suscepti-
ble to dexamethasone and antigen receptor–mediated cell
death (22, 23). The effect of the p53 mutation has been
mapped upstream of apoptotic mitochondrial events (55).
Therefore, we tested whether p53 is a target for Cdk2
activity during thymocyte apoptosis after g-irradiation. In
vitro kinase assays using immunoprecipitated Cdk2 from
g-irradiated and dexamethasone-treated thymocytes showed
that Cdk2 can phosphorylate p53 (Fig. 5 A). Moreover,
p53 was found to associate with Cdk2 in thymocytes (Fig.
5 B). To test the effect of Cdk2 activity on p53 expression,
we analyzed the levels of p53 protein in g-irradiated thy-
mocytes in the presence or absence of Cdk2 inhibitors. Al-
though p53 protein accumulated to significant levels after
treatment of cells with g-irradiation alone, little p53 accu-
mulation was observed when cells were treated with g-irra-
diation in the presence of Cdk2 blockers (Fig. 5 C). Irradi-
ation-induced p53 protein accumulation was caused by
enhanced p53 protein stability but not by p53 gene transac-
tivation (not shown).
To further corroborate the regulation of p53 by Cdk2,
we examined the expression of the p53-inducible death
promoter Bax (56–58) by Northern blotting. Induction of
thymocyte apoptosis by g-irradiation led to an increase in
Bax transcripts, and Bax transactivation was found to de-
pend on Cdk2 activity (Fig. 5 D). In dying thymocytes we
found only induction of the p53-regulated death promoter
Bax but not transactivation of the p53-regulated gene p21
(not shown). Cdk2 kinase activity was normally induced in
g-irradiated p532/2 thymocytes (not shown), indicating
that p53 is downstream of Cdk2 in the thymocyte death
signaling cascade. Since thymocytes from p532/2 mice are
not resistant to dexamethasone or antigen receptor–medi-
ated apoptosis, other molecules must exist that link Cdk2
activation to cell death.
Discussion
The identification of Cdk2 as a master regulator of cell
death provides the first evidence for a shared signaling
pathway that integrates multiple death signaling pathways
into a common death effector cascade in developing thy-
mocytes. The hierarchy of Cdk2 action suggests that Cdk2
is the earliest known common signaling element required
for thymocyte apoptosis in response to environmental and
developmental cues such as negative selection. This hy-
pothesis is based on the following findings: (a) all nonspe-
cific (g-irradiation, heat shock, dexamethasone) and spe-
cific (peptide-mediated thymocyte cell death) apoptotic
stimuli tested induce rapid activity of the cyclin-dependent
kinase Cdk2 in noncycling thymocytes; (b) Cdk2 acts up-
stream of the opening of mitochondrial pores, Bcl-2 family
proteins, caspase activation, p53, and proteolytic processing
of Rb; (c) inhibition of Cdk2 completely protects thy-
mocytes from g-irradiation, heat shock, dexamethasone,
PMA, anti-CD3, and peptide-mediated cell death; (d) Cdk2
and the tumor suppressor, p53, constitutively associate in
thymocytes and activated Cdk2 isolated from apoptotic
thymocytes can phosphorylate p53; (e) Cdk2 regulates p53
protein accumulation and transactivation of the p53-induc-
ible death promoter, Bax, after g-irradiation. These data
provide the first link between the cell cycle machinery and
apoptosis in normal development and differentiation and
indicate that Cdk2 is a crucial kinase that mediates cell
death in thymocyte maturation and thymocyte selection.
Our results indicate that after g-irradiation, Cdk2 phos-
phorylates and stabilizes p53, which then transactivates the
death promoter Bax. Interestingly, in dying thymocytes we
found only induction of the p53-regulated death promoter
Bax but not transactivation of the p53-regulated gene p21
(59), suggesting that only certain gene loci are accessible for
p53 transactivation or that other cofactors act in concert
with p53 to modulate gene expression in a tissue- and lin-
eage-specific manner. Although p53 protein levels were in-964 Cdk2 in Thymocyte Apoptosis
creased in thymocytes after dexamethasone and g-irradia-
tion, it has been shown in p53 gene–deficient mice that
p53 protects thymocytes only from DNA damage, and not
from dexamethasone or antigen receptor–mediated cell
death (22, 23), implying that other downstream molecules
exist that link Cdk2 to apoptosis. Preliminary evidence
from our laboratory implies that the glucocorticoid recep-
tor which is required for dexamethasone-mediated cell
death can be phosphorylated by activated Cdk2 and coim-
munoprecipitates with Cdk2 in dying thymocytes. Besides
association with the ligand, phosphorylation of the gluco-
corticoid receptor is required for its translocation from the
cytoplasm into the nucleus (60–62). In addition to the glu-
cocorticoid receptor, other orphan steroid receptors such as
Nur77 might be molecular targets for Cdk2 kinase activity.
It has been shown that mitochondria are early check-
points that integrate multiple death signaling pathways into
a common Ced4/caspase-regulated effector mechanism.
Opening of mitochondrial pores, mitochondrial swelling,
disruption of DCm, and release of proapoptotic molecules,
including cytochrome c and apoptosis-inducing factor (AIF),
from the mitochondrial intermembrane spaces into the cyto-
plasm have all been implicated as fundamental mechanisms
that initiate and propel the effector phase of apoptosis.
Posttranslational modification and the balance between death
suppressors, such as Bcl-2 and Bcl-XL, and death pro-
moters, including Bax and Bad, are crucial mechanisms of
mitochondrial integrity and the apoptotic effector phase
(9, 49). Our results show that Cdk2 acts upstream of DCm
disruption, Bax and Bcl-2, and caspase activation in devel-
oping thymocytes. Moreover, whereas loss of the mito-
chondrial transmembrane potential can only be observed 2 h
after addition of death stimuli, Cdk2 kinase activity is in-
duced very rapidly and a “point of no return” was reached
between 15 and 30 min after treatment with the apoptotic
stimulus, such that a Cdk2 blocker added after this time
was unable to prevent apoptosis. Thus, our results indicate
that Cdk2 is the earliest known common denominator that
can integrate many independent apoptotic signals into one
common effector pathway.
Although CD95 (Fas) stimulation induced Cdk2 activity
in thymocytes, inhibition of Cdk2 did not block CD95-
mediated apoptosis. In fact, Cdk2 inhibition enhanced the
susceptibility to CD95 killing. So far, CD95-mediated apop-
tosis is the only death signal in thymocytes that does not
rely on Cdk2 activation. Although apoptosis in response to
g-irradiation, heat shock, dexamethasone, or peptide-spe-
cific negative thymocyte selection requires active transcrip-
tion of death genes, apoptosis after CD95 killing can occur
in the presence of RNA or protein synthesis inhibitors (9).
Figure 5. P53 is a substrate for Cdk2 activity. (A) Phos-
phorylation of p53 by Cdk2. p53 phosphorylation was deter-
mined after g-irradiation (500 rads), dexamethasone treatment
(1 mM), or no treatment (Control). Thymocytes were cul-
tured and harvested as described in the legend to Fig. 1. Cdk2
was immunoprecipitated, and Cdk2 activity was determined
using recombinant human p53 as the substrate. The levels of
phosphorylated p53 (top), p53 protein (middle), and Cdk2
protein (bottom) are shown. (B) Coimmunoprecipitation of
p53 and Cdk2. Thymocytes were harvested 2 h after g-irradi-
ation (500 rads) or after 2 h culture without a death stimulus (Control). Western blot analysis was per-
formed after immunoprecipitation (IP) using an anti-Cdk2 Ab and blotting with anti-p53 and anti-Cdk2.
Similar results were obtained using p53 immunoprecipitations. One result representative of three indepen-
dent experiments is shown. (C) Levels of p53 protein. Thymocytes were cultured for 2 h after g-irradiation
(500 rads) or the absence of a death stimulus (Control) in the presence or absence of roscovitine (50 mM,
Rosco). Cells were lysed, and extracts were analyzed by Western blotting using anti-p53 and anti–Bcl-XL
Abs. One result representative of three independent experiments is shown. (D) Induction of Bax mRNA.
Thymocytes were cultured as described in B and harvested after 3 h. 10 mg total RNA was Northern blot-
ted and hybridized to probes for both Bax and b-actin (loading control). Hybridization with the Bax probe
shows two alternatively spliced RNA transcripts of 1.5 and 1.0 kb. The increase in Bax mRNA induced by
g-irradiation is abolished in the presence of roscovitine (50 mM).965 Hakem et al.
Moreover, enucleated cells can undergo apoptosis after
CD95 activation, suggesting that all components necessary
for CD95-mediated apoptosis are present in cells and that
CD95 activation can directly trigger the apoptotic machin-
ery. It should be noted that both Cdk2 inhibitors rosco-
vitine and olomoucine do not prevent transcription or
translation in noncycling neurons (63) and that inhibition
of Cdk2 did not regulate transactivation of the FasL in thy-
mocytes (not shown).
The specific Cdk2 blockers olomoucine and roscovitine
are purine analogues that inhibit Cdk2 kinase activity by
specifically binding to the Cdk2 ATP-binding site (39, 40).
At concentrations at which olomoucine and roscovitine
blocked apoptosis in in vivo thymocyte cultures, these in-
hibitors had no effects on in vitro kinase activity of PKCa-z,
Cdk4, Cdk6, Abl, cAMP- or GMP-dependent protein ki-
nases (PKA, PKG), mitogen-activated protein kinase (MAPK;
extracellular signal regulatory kinase [ERK]1, ERK2), Src
family kinases, glycogen synthase kinase 3 (GSK3), casein
kinase, receptor tyrosine kinases, myosin light chain kinase,
p38/HOG, or stress-activated protein kinase (SAPK)/c-Jun
NH2-terminal kinases (JNKs) (39; and data not shown).
Through their unique selectivity for Cdk2, roscovitine and
olomoucine provide a unique opportunity to study the role
of Cdk2 in thymocyte apoptosis. However, we cannot ex-
clude that roscovitine and olomoucine inhibit a yet un-
identified kinase, and our results need to be confirmed using
genetic model systems. Thus, genetic systems for inducible
and thymocyte-specific inactivation/activation of Cdk2
need to be developed in the future. However, our results
showing that all death stimuli lead to Cdk2 kinase activity
in thymocytes and that two different Cdk2 kinase inhibi-
tors, but not other inhibitors that block G1 to S progres-
sion, inhibit thymocyte apoptosis strongly suggest that
Cdk2 is a key kinase involved in thymocyte apoptosis.
Cdk2 is crucial for the progression from the G1 to the S
phase of the cell cycle. Inhibition of Cdk2 activity in vitro
has been shown to protect cultured sympathetic neurons
and heart muscle cells from apoptosis (26, 27). Our results
in noncycling CD41CD81 thymocytes provide the first
evidence that Cdk2 has a crucial role in the induction of
cell death during normal development. However, it has
been shown that Cdk2 inhibition can also lead to cell death
in tumor cell lines, and Cdks are frequently deregulated in
tumors (28). Similarly, we found that in contrast to devel-
oping, noncycling thymocytes, inhibition of Cdk2 in four
different thymic lymphoma cell lines led to rapid apoptosis
and sensitized T cell tumors to anti-CD3, dexamethasone,
or g-irradiation–mediated cell death (not shown). These
results suggest that Cdk2 has functions in the apoptotic
processes that regulate normal development which are
distinct from those in tumorigenesis and transformation.
Thus, specific inhibition of Cdk2 could be exploited to
sensitize tumor cells to apoptosis by anticancer drugs,
whereas molecular inhibition of Cdk2 might protect nor-
mal, noncycling cells from the adverse effects of the same
drugs.
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